About Necitumumab
            
            Class: | Monoclonal antibody (EGFR inhibitor)  
Use: | Treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin  
Adult dose: | 800 mg administered as an intravenous infusion once every 2 weeks, starting on the first day of chemotherapy  
Pediatric dose: | Safety and efficacy have not been established in pediatric patients  
Side effects: | Common side effects include rash, hypomagnesemia, diarrhea, fatigue, and nausea  
Contraindications:
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (EGFR inhibitor)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin
                 
                
                
                    
                        Storage Requirements
                    
                    Store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Eli Lilly & Co Inc., U.S.A
                    
                    
                    Package Size
                    1 Glass Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 21403.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        800 mg administered as an intravenous infusion once every 2 weeks, starting on the first day of chemotherapy
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy have not been established in pediatric patients
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include rash, hypomagnesemia, diarrhea, fatigue, and nausea
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Known hypersensitivity to necitumumab or any component of the formulation; history of severe infusion-related reactions
         
        
        
            
                Important Warnings
            
            Risk of severe skin reactions, infusion-related reactions, and hypomagnesemia; monitor magnesium levels and provide supplementation as needed; caution in patients with a history of cardiac disease due to potential for cardiac events
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.